Zymeworks Receives Inaugural Biotech Rising Star Award at the 14th Annual C21 BioVentures™ Conference

May 25, 2012

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, announced today that it had been selected as the recipient of the inaugural Biotech Rising Star award as judged by a panel of distinguished venture capitalists and industry leaders. The award was presented at the C21 BioVentures™ conference held in Napa, California on May 24, 2012.

The presentation of the Biotech Rising Star Award recognized the top company presenter at the C21 BioVentures™ conference, based on their business plan, market potential, investment interest, innovation, creativity and team member credentials. A select field of 30 attending companies were judged by a selection committee consisting of noted members of the venture capital industry including Dr. Michael Ross (Managing Partner, SV Life Sciences), Dr. Heather Preston (Managing Director, TPG Biotech), Dr. Mahendra G. Shaw (Partner, Vivo Ventures), Ms. Nola Masterson, (Managing Director, Science Futures, Inc.), and others.

“We are honored by the recognition of the Rising Star selection committee, especially in such a distinguished crowd of competing presenting companies,” says Dr. Ali Tehrani, Zymeworks’ President & CEO. “Since the announcement of the strategic collaboration with Merck, Zymeworks has significantly advanced its Azymetric™ and AlbuCORE™ programs, and the pending announcement of our own best-in-class therapeutics pipeline will just increase the excitement around the application of our bi-specific and muli-valent platforms in areas of unmet medical need.”

About Zymeworks Inc.

Zymeworks is a privately held biotechnology company that is developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on growing its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. More information on Zymeworks can be found at http://www.zymeworks.com.

Contact

Zymeworks Inc.
Dr. Ali Tehrani, Ph.D.
President & CEO
info@zymeworks.com

Source

Zymeworks Inc.